



Attorney Docket No.: 4409.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jonassen et al.

Serial No.: 09/772,607

Group Art Unit: 1653

Filed: January 30, 2001

Examiner: Kam, C.

For: Protracted Polypeptides

Confirmation No. 2082

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This Amendment is submitted in response to the Office Action mailed May 31, 2002 in which the Examiner rejected claims 20-46. Reconsideration is respectfully requested in view of the following amendments and remarks.

IN THE SPECIFICATION:

Please replace the paragraph at page 9, line 26 to page 10, line 5 with the following:

E1
For-Nle-Leu-Phe-Nle-Tyr-Lys-OH (SEQ ID NO: 7), was purchased from Bachem Feinchemikalien AG, Switzerland. The peptide is a potent chemoattractant for human neutrophils. The title compound was prepared by dissolving 17 mg of For-Nle-Leu-Phe-Nle-Tyr-Lys-OH (SEQ ID NO: 7) in 5 ml of DMF and then adding 35 µl of triethylamine followed by 20 mg of solid tetradecanoic acid succinimidyl-N-hydroxy ester to the solution. The reaction was monitored by RP-HPLC employing a column packed with reversed phase C18 silica material. For the elution was used a gradient from 30% ethanol to 80 % ethanol in 0.1% aqueous TFA. The product was purified on a column (length 250 mm diameter 20 mm) packed with C18 silica reversed phase